GLOBAL DUPUYTRENS DISEASE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The global Dupuytren’s disease market size is valued at US$ 4.3 Bn in 2023 and is expected to reach US$ 5.9 Bn by 2030, growing at a compound annual growth rate (CAGR) of 4.6% from 2023 to 2030.

There are two main types of treatments for Dupuytren's disease – non-surgical and surgical. Non-surgical treatments include needle fasciotomy, collagenase clostridium histolyticum (CCH) injections, and radiation therapy. Needle fasciotomy uses a needle to break up dense collagen in the fascia. This can reduce finger contracture but the condition often returns. CCH injections involve injecting an enzyme called collagenase into the cord to break it down. This allows for temporary straightening of the finger. However, similar to needle fasciotomy, the contracture may come back. Radiation therapy uses x-rays to damage the fibroblasts in the fascia to potentially stop progression, but the evidence for its effectiveness is limited.

The main surgical treatments are fasciectomy and dermofasciectomy. A fasciectomy cuts out the collagen cords causing contracture. A dermofasciectomy removes both the fascia and the overlying skin. While surgery provides effective long-term correction, risks include nerve damage, infection, complex regional pain syndrome, and recurrence which is common in aggressive recurrent disease. In summary, there are non-surgical and surgical options to address symptoms but the condition often returns due to its progressive nature.

Analyst’s Views:

The global Dupuytren's disease market is expected to grow steadily over the forecast period owing to the rising prevalence of the disorder across various regions. North America currently dominates the market due to growing awareness levels and availability of advanced treatment options. However, Asia Pacific is likely to emerge as the fastest growing region with rising medical tourism leading to increased diagnosis and treatment rates.

The market is driven by factors such as increasing geriatric population prone to developing Dupuytren's disease, rising focus on early diagnosis and treatment, and growing number of clinical trials evaluating novel treatment alternatives. Moreover, improving healthcare infrastructure and expanding patient pool indicate promising growth opportunities. However, high cost of surgical procedures remains a major restraint in developing markets.

Important opportunities lie in the development of new drugs targeting the disease's pathological processes. Minimally invasive procedures could also gain favor over extensive hand surgeries due to their advantages of faster recovery times and lower risks of complications. Outpatient care settings are expected to gradually replace hospital-based treatment models. Collaborations between players for developing combination therapies may further expand the available treatment options. Overall, the Dupuytren's disease market prospects appear bright with ongoing research and development activities.

Global Dupuytren’s Disease Market Regional Insights

• North America: North America is the largest market for Dupuytren’s disease, accounting for a share of over 33.5% in 2023. North America has established its dominance in the global Dupuytren's disease market over the years. With U.S. being the major contributor, the region is home to several leading pharmaceutical and medical device companies. Improving healthcare infrastructure, high awareness levels, and expanding patient pool have made North America the most attractive market.
• Europe: Europe is the second-largest market for Dupuytren’s disease, accounting for a share of over 26.1% in 2023. European countries have been adopting innovative medical treatment options for treating the disease. The emphasis on the adoption of inorganic growth strategies, such as partnerships and focus on research and development activities in the region, is expected to drive the regional market growth over the forecast period.
• Asia Pacific: Asia Pacific is the fastest-growing market for Dupuytren’s disease, accounting for a share of over 20.3% in 2023. The Dupuytren's disease market in Asia Pacific region has been witnessing rapid growth supported by improving medical technologies and rising healthcare expenditures. In particular, countries like China, India, and Japan have turned into hotspots owing to their huge patient populations and increasing economic capabilities.

Figure 1. Global Dupuytren’s Disease Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Global Dupuytren’s Disease Market Drivers:

• Increasing prevalence of Dupuytren’s disease: The prevalence of Dupuytren’s disease is expected to drive the growth of the market over the forecast period. For instance, according to data published in October 2020 by the National Library of Medicine, the prevalence of Dupuytren’s disease in the world is found to be 8.2% (95% CI 5.7–11.7%). The highest prevalence rate is reported in Africa with 17.2% (95% CI 13–22.3%) in 2020.
• Increasing research and development activities: Increasing research and development activities by the key players in the market are expected to drive the growth of the market over the forecast period. For instance, in June 2022, a research team at the Kennedy Institute, University of Oxford, based in U.K., led by Professor Jagdeep Nanchahal have proven that the anti-TNF drug adalimumab is effective in treating patients with early stage Dupuytren’s disease.
• Increasing awareness of Dupuytren's disease: One of the key drivers contributing towards the growth of Dupuytren's disease market is the increasing awareness about the condition. Dupuytren's disease is a hereditary disease that causes thickening and contraction of the palmar fascia in the hand resulting in fingers curling inward towards the palm. However, for a long time this condition remained under-diagnosed majorly due to lack of awareness among both patients and physicians. Now, with increasing efforts by medical practitioners, patient advocacy groups and pharmaceutical companies, awareness levels have risen significantly. Various awareness campaigns and educational initiatives are bringing Dupuytren's disease into the spotlight and enabling correct diagnosis. For example, support groups are educating how this condition is different from other musculoskeletal problems and emphasize on early intervention. Also, the recent recognition of Dupuytren's disease as a real medical condition by leading medical bodies has endorsed it as an area that requires more clinical research and treatment innovation. This recognition has prompted more discussions around the disease in peer reviewed journals, patient conferences, and social media. As a result of the growing awareness, patients who may have early symptoms are now able to recognize it and seek medical help in a timely manner rather.
• Growing geriatric population: As the world population is aging rapidly, more and more people are falling prey to Dupuytren's disease. Old age is one of the major risk factors for this condition as the incidence and prevalence of Dupuytren's disease increases with increasing age. According to some estimations, Dupuytren's disease affects nearly 10% of the population aged over 60 years and 20% of the population aged over 80 years. With increased life expectancy and declining birth rates, countries around the world are witnessing a consistent rise in the percentage of the geriatric population in their total population. This demographic shift is expected to significantly fuel the need for effective treatment procedures of age-related conditions such as Dupuytren's disease in the coming years. With a growing pool of aging individuals worldwide, the global Dupuytren's disease market is poised to experience substantial growth over the next decade

Global Dupuytren’s Disease Market Opportunities:

• Emerging economies: Emerging economies in regions like Asia Pacific, Latin America, Africa, and Eastern Europe present a huge opportunity for growth in the global Dupuytren's disease market. These regions are expected to see higher epidemiological occurrences of Dupuytren's disease in the coming years due to transformations in lifestyles, dietary habits and rising levels of obesity. Countries like India, China, Brazil, Mexico, Indonesia, and Nigeria have a very large patient pool suffering from undiagnosed or undermanaged Dupuytren's disease. As economic conditions and access to healthcare facilities improve in these nations, there will likely be a greater focus on diagnosing and treating previously neglected conditions like Dupuytren's disease.
• Expanding medical technologies: Expanding medical technologies offer a great opportunity for growth in the global Dupuytren’s disease market. Dupuytren’s disease is a progressive condition characterized by the growth of fibrous cords under the skin of the palm, which can slowly deform the fingers and reduce the hand's function. As of now, the only definitive treatment is surgical fasciectomy which removes these fibrous cords. However, the surgery often requires extensive wound healing and hand therapy, with potential risks of complications and relapse. Recent advancements in medical technologies present minimally invasive procedures that overcome many of the challenges associated with open fasciectomy. For example, needle aponeurotomy uses needles to break up problematic cords within the palm and fingers. This offers relief from hand deformity while avoiding significant wounds and scarring. Similarly, collagenase injections have emerged as a non-surgical option for early-stage Dupuytren’s disease. Collagenase works by enzymatically dissolving the collagen cords, reducing contractures in a brief office procedure. According to statistics from Public Health England, collagenase treatment volumes have increased over 300% from 2018 to 2021 in the UK National Health System, reflecting its growing acceptance as an efficacious front-line therapy
• Increasing initiatives by the key players in the market: Increasing initiatives by the key players in the market are expected to drive the growth of the market over the forecast period. For instance, on May 17, 2023, Ventoux Biosciences, a pharmaceutical company, announced the launch of its efforts to deliver life-changing therapies for patients with Dupuytren’s disease, a common, progressive, and debilitating fibrotic contracture that limits hand mobility. Ventoux Biosciences aims is to identify and develop novel treatments that will help patients across the full spectrum of the disease by delaying or reversing further progression.
• Increasing research and development activities: Increasing research and development activities by the key players are expected to drive the growth of the market over the forecast period. For instance, on June 26, 2023, Endo International plc, a global pharmaceutical company, announced that the first patient has been enrolled in Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren's Contracture (GRASP-DC), a non-interventional registry of up to 1,000 patients with Dupuytren's contracture (DC). This registry will create the largest and most comprehensive collection of real-world DC data on treatment outcomes.

Global Dupuytren’s Disease Market Trends:

• Focus on combination therapy: The trend of combination therapy is having a significant impact on the global Dupuytren's disease market. Dupuytren's disease is a progressive fibromatosis condition affecting the hands. Traditional treatments have involved surgery or needle fasciotomy to release or remove fibrous tissues. However, there is now a growing focus on combining these interventions with additional non-surgical therapies to improve outcomes. Surgery or needle fasciotomy with collagenase clostridium histolyticum (CCH) injections have become an increasingly popular treatment approach. CCH works by enzymatically dissolving the collagen in fibrous cords. Using CCH both before and after surgical release of cords allows for better straightening of the affected fingers. According to the Phase III clinical trial results published by the manufacturer in 2021, over 70% of patients achieved successful finger extension compared to around 50% with surgery alone. Combining interventions in this way reduces the need for multiple surgeries and leads to improved hand function.
• Shift towards minimally invasive procedures: The trend towards minimally invasive procedures is having a significant influence on the global Dupuytren's disease market. However, over the past decade, there has been a marked shift towards minimally invasive surgical procedures for treating this condition. Minimally invasive procedures, such as needle fasciotomy, collagenase clostridium histolyticum injection, and others, percutaneous release techniques are becoming increasingly popular as they are associated with less post-operative pain, quicker recovery times, and comparable clinical outcomes to open fasciectomy.
• Increasing awareness about the disease Increasing awareness about the disease is expected to drive the growth of the market over the forecast period. For instance, in October 2022, Endo International plc, a pharmaceutical company, announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's contracture (DC), a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm.
• Increasing demand for biosimilars: The increasing demand for biosimilars is having a significant impact on the global Dupuytren's disease market. Biosimilars are biologic medical products that are developed to be similar to an existing approved biologic product, referred to as the reference product. In recent years, there has been tremendous growth in the development and approvals of biosimilars for the treatment of various medical conditions. This rise in biosimilar approvals and availability is influencing treatment patterns for Dupuytren's disease as well. Dupuytren's disease is a progressive fibroproliferative disorder affecting the hand and fingers. Traditionally, surgery was the mainstay of treatment for advanced cases. However, the approval of the first biologic therapy, collagenase clostridium histolyticum (CCH) in 2010 provided an important non-surgical option. CCH received widespread adoption and largely dominated the Dupuytren's disease treatment landscape over the past decade.

Global Dupuytren’s Disease Market Restraints:

• High cost of treatment: This high cost puts the surgery out of reach for many patients without proper health insurance. Patients sometimes find themselves unable to pay high co-pay requirements, even for those who have insurance. For instance, according to data published in July 2022 by Dotdash Media, Inc., a digital media company, average Dupuytren’s disease costs in the U.S. range between US$ 15,000 and US$ 30,000.
• Risks and complications associated with surgery: Surgery has traditionally been the primary treatment option for Dupuytren's disease. However, surgical procedures come with risks of complications that give patients pause. All surgeries carry risks of infection, nerve damage, joint stiffness, and recurrence of the disease. For Dupuytren's disease, which commonly affects the elderly population, these risks weigh heavy on patients and surgeons who must consider factors like healing time and recovery. The invasive nature of surgery itself poses drawbacks like postoperative pain, discomfort, and tenderness that can extend recovery periods substantially. For many elderly patients suffering from multiple conditions already, major surgery may not seem worth the added stress, pain, and risks to their health.

Recent Developments

New product launches

• On August 3, 2023, 180 Life Sciences Corp., a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced that it has submitted a request to the U.K.’s  Medicines and Healthcare products Regulatory Agency (MHRA) for a follow up scientific advice meeting where the company will seek guidance on a plan to obtain Conditional Marketing Authorization (CMA) for the use of adalimumab in the treatment of early stage Dupuytren’s disease.

Figure 2. Global Dupuytren’s Disease Market Share (%), by Disease Type, 2023

To learn more about this report, request sample copy

Top Companies in the Global Dupuytren’s Disease Market

• Endo International Plc
• Bristol-Meyers Squibb Company
• Spear Pharmaceuticals
• GSK Plc.
• AstraZeneca
• Hikma Pharmaceuticals Plc
• LEO Pharma A/S
• Fresenius Kabi AG
• Bayer AG
• Novartis AG
• Pfizer Inc.
• Nantong Jinghua Pharmaceutical Co., Ltd.
• Actiza Pharmaceutical Pvt. Ltd.
• 180 Life Sciences Corp

Definition: Dupuytren's disease is an abnormal thickening of fascia, a layer of tissue under the skin, in the palm of the hand at the base of the fingers.